Methods for the classification of leprosy for treatment purposes

Clinical Infectious Diseases

Volumn 44, Issue 8, 2007, Pages 1096-1099

  Pardillo, Fe Eleanor F ^a   Fajardo, Tranquilino T ^a   Abalos, Rodolfo M ^a   Scollard, David ^b   Gelber, Robert H ^b,c  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN; LEPROSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NONHUMAN; PAUCIBACILLARY LEPROSY; PHILIPPINES; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; WORLD HEALTH ORGANIZATION; CLASSIFICATION; METHODOLOGY; PATHOLOGY; SKIN;

CLASSIFICATION; HUMANS; LEPROSTATIC AGENTS; LEPROSY; SKIN; WORLD HEALTH ORGANIZATION;

EID: 33947534530     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/512809     Document Type: Article

References (18)

1. Ridley DS, Jopling WH. Classfication of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis 1966; 34:255-73.
2. World Health Organization (WHO). Chemotherapy of leprosy for control programmes. WHO Technical Report Series, no. 675. Geneva: World Health Organization, 1982.
3. World Health Organization (WHO). WHO Expert Committee on Leprosy: 6th report. WHO Technical Report Series, no. 768. Geneva: World Health Organization, 1988.
4. World Health Organization (WHO). Guide to eliminate leprosy as a public health problem. 1st ed. Geneva: World Health Organization, 1995.
5. World Health Organization (WHO). WHO Expert Committee on Leprosy: 7th report. WHO Technical Report Series, no. 874. Geneva: World Health Organization, 1998.
6. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York, NY: John Wiley and Sons, 1981:40.
7. Ridley DS, Jopling WH. A classification of leprosy for research purposes. Leprosy Review 1962; 33:119-28.
8. Oskam L. Diagnosis and classification of leprosy. Leprosy Review 2002; 73:S17-26.
9. Becx-Bleumink M. Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy - a comparison of methods based mainly on skin smears as opposed to clinical methods-alternative clinical methods for classification of patients. Int J Lepr Other Mycobacterial Dis 1991; 59:292-303.
10. Groenen G, Saha NG, Rashid MA, et al. Classification of leprosy cases under field conditions in Bangladesh: I. usefulness of skin smear examinations. Lepr Rev 1995; 66:126-33.
11. Van Brakel WH, de Soldenhoff R, McDougall AC. The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. Lepr Rev 1992; 63:231-46.
12. Croft RP, Smith WC, Nicholls P, Richardus JH. Sensitivity and specificity of methods of classification of leprosy without use of skin-smear examination. Int J Lepr Other Mycobact Dis 1998; 66:445-50.
13. Dasananjali K, Schreuder PA, Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996. Int J Lepr Other Mycobact Dis 1997; 65:28-36.
14. Buhrer-Sekula S, Sarno EN, Oskam L, et al. Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis 2000; 68:456-63.
15. Cellona RV, Balagon MF, de la Cruz EC, et al. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis 2003; 71:308-19.
16. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000; 71:144-53.
17. Jamet P, Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 1995; 63:195-201.
18. Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Microbact Dis 2004; 72:493-500.